Gain Therapeutics Inc's Comment on Sales, Marketing and Customers
The FDA's regulatory framework includes the Orphan Drug Designation for drugs intended to treat rare diseases affecting fewer than 200,000 individuals in the United States or conditions where recovering development costs is unlikely. This designation provides incentives such as tax credits and fee waivers for companies developing orphan products. Orphan drugs may also receive seven years of marketing exclusivity, which can prevent competitors from marketing the same drug for the designated indication during that period. Additionally, the FDA offers expedited development and review programs, including Fast Track designation, Breakthrough Therapy designation, Priority Review, and Accelerated Approval, to facilitate faster access to drugs addressing serious or life-threatening diseases or conditions.
Gain Therapeutics, a pioneering biotechnology firm focused on advancing treatments for neurodegenerative disorders, recently announced the initiation of a Phase 1b clinical trial for its lead candidate, GT-02287. This ambitious study aims to assess the safety, tolerability, and preliminary efficacy of GT-02287 in individuals suffering from GBA1 (Glucocerebrosidase gene mutations) and idiopathic Parkinson’s disease, a common form of Parkinson s that arises without any genetically identifiable cause. The trial is set to take place in Australia, where the company has successfully received regulatory approval to start patient enrollment. Understanding GBA1 and Idiopathic Parkinson s Disease The GBA1 mutation h...
: Gain Therapeutics is set to host a virtual webinar that will address the critical results from its Phase 1 clinical study of GT-02287, a small molecule therapy designed to target glucocerebrosidase (GCase) activity to improve outcomes in patients with Parkinson s disease. The webinar is anticipated to emphasize the positive responses gathered during the International Movement Disorder Society (MDS) Congress and provide detailed insights into the design of the forthcoming Phase 1b trial.Parkinson’s disease, a neurodegenerative disorder characterized by motor dysfunction and cognitive decline, has long challenged researchers and clinicians alike. The disease’s complex pathophysiology often involves a gen...
Gain Therapeutics Achieves Key Milestones in Phase 1 Study of GT-02287, a Promising Small Molecule Therapy for Parkinson s Disease Bethesda, Md. - Gain Therapeutics, Inc. (Nasdaq: GANX), a clinical-stage biotechnology company pioneering the discovery and development of next-generation allosteric small molecule therapies, has announced the completion of dosing in the Multiple Ascending Dose (MAD) part of its Phase 1 clinical study for GT-02287. This novel small molecule therapy is designed to target the GCase enzyme, a key player in the pathology of GBA1 Parkinson s disease.GT-02287 has shown encouraging safety and tolerability across both the Single Ascending Dose (SAD) and MAD components of the Phase 1 st...
Gain Therapeutics, a leading biotechnology company focusing on developing breakthrough therapeutics for neurological disorders, recently presented their latest data at the Federation of European Neuroscience Societies (FENS) Forum 2024. The data showcased remarkable improvements in both cognitive and motor function in a preclinical model of GBA1 Parkinson s disease, thereby providing a promising avenue for potential therapeutic interventions in this debilitating condition.
Parkinson s disease is a progressive neurodegenerative disorder characte...
In a groundbreaking development, Gain Therapeutics, Inc. (Gain) has announced encouraging outcomes from the single ascending dose (SAD) phase of its Phase 1 clinical trial involving GT-02287. As a novel small molecule therapy specifically targeting GCase for GBA1 Parkinson s Disease, GT-02287 has shown exceptional safety, tolerability, and plasma exposure levels. The positive results have further solidified its potential as a leading and first-in-class treatment option.Background:GBA1 Parkinson s Disease is a subtype of Parkinson s disease caused by mutations in the GBA1 gene, leading to dysfunctional glucocerebrosidase enzyme (GCase). This deficiency contributes to the accumulation of toxic protein clusters...
Gain Therapeutics, a clinical-stage biotechnology company, has recently initiated the Multiple Ascending Dose (MAD) part of the Phase 1 clinical trial for GT-02287, their lead drug candidate targeting GBA1 Parkinson s disease. In this article, we will delve into the significance of this trial and the potential implications for patients suffering from this debilitating neurodegenerative disorder. Additionally, we will explore the promising preclinical data presented by Gain Therapeutics on the therapeutic effects of GT-02287 in models of Parkinson s disease and GM1 Gangliosidosis.The Challenge of GBA1 Parkinson s Disease:GBA1 Parkinson s disease is a rare variant of Parkinson s disease that is caused by a mut...
Advancements in Therapeutic Approach for Parkinson s Disease: The Potential of GT-02287:Parkinson s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the brain, leading to motor dysfunction, cognitive impairment, and other debilitating symptoms. While current treatments primarily focus on managing symptoms, there is an urgent need for disease-modifying therapies that can slow or halt the progression of PD. In this context, Gain Therapeutics groundbreaking research and development efforts have led to the discovery of GT-02287, a promising potential treatment for PD. This article aims to provide an in-depth analysis of the new data on GT-02287 as presented at th...
Gain Therapeutics Inc’s Comment on Sales, Marketing and Customers
The FDA's regulatory framework includes the Orphan Drug Designation for drugs intended to treat rare diseases affecting fewer than 200,000 individuals in the United States or conditions where recovering development costs is unlikely. This designation provides incentives such as tax credits and fee waivers for companies developing orphan products. Orphan drugs may also receive seven years of marketing exclusivity, which can prevent competitors from marketing the same drug for the designated indication during that period. Additionally, the FDA offers expedited development and review programs, including Fast Track designation, Breakthrough Therapy designation, Priority Review, and Accelerated Approval, to facilitate faster access to drugs addressing serious or life-threatening diseases or conditions.
Sources:
Gain Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Gain Therapeutics inc’s corporate clients.
For your research, we’ve provided 9 tables on Gain Therapeutics inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
